UbiquiTx

UbiquiTx is a biotechnology company pioneering a next-generation proteome editing platform to develop therapies for life-threatening diseases. The company’s core technology, Chimeric Ligands for Induced Proximity (CLIPs), utilizes AI-designed peptides to recruit specific enzymes that can degrade, stabilize, or otherwise modulate "undruggable" protein targets. UbiquiTx is initially focusing its pipeline on liver diseases, including severe alcoholic hepatitis and intrahepatic cholangiocarcinoma, while also exploring applications in oncology and viral infections. By combining deep learning-driven binder design with mRNA-based delivery, the company aims to create programmable and modular treatments that offer high specificity and tunability.